prism
(3)
ESC Spectrum makes the smokestack show its work
A plant can measure its emissions and still struggle to explain them. ESC Spectrum sells the instruments, software, and human expertise that turn a stream of readings into a record someone can defend.
Unison and the art of making 3,800 contracts behave
One federal agency needed thousands of contracts changed. Unison’s answer reveals the peculiar appeal of software that knows the rules, remembers the paperwork, and leaves the judgment to people.
Enveda
Enveda is a clinical-stage biotech that uses artificial intelligence to read the chemistry of the natural world and turn it into new medicines. Founded in 2019 by Viswa Colluru, the company built PRISM, a foundation model trained on more than a billion mass spectra, to decode the structure of natural molecules that traditional methods leave invisible. That platform has produced a pipeline of small-molecule drug candidates - led by ENV-294, an oral anti-inflammatory now in Phase 2 trials for atopic dermatitis and asthma. Backed by more than $700M in funding and valued as a unicorn, Enveda operates out of Boulder, Colorado and Hyderabad, India.